Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 31 articles:
HTML format
Text format



Single Articles


    November 2018
  1. RADHAKRISHNAN R, Ha JH, Jayaraman M, Liu J, et al
    Ovarian Cancer Cell-derived Lysophosphatidic Acid Induces Glycolytic Shift and Cancer-associated Fibroblast-Phenotype in Normal and Peritumoral Fibroblasts.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30689.
    PubMed     Text format     Abstract available


    October 2018
  2. PENG Y, Kajiyama H, Yuan H, Nakamura K, et al
    PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
    Cancer Lett. 2018;442:181-192.
    PubMed     Text format     Abstract available


    August 2018
  3. YANG Z, Jin P, Xu S, Zhang T, et al
    Corrigendum to "Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer" [Cancer Lett. 2018 Feb 28; 415:20-29].
    Cancer Lett. 2018 Aug 18. pii: S0304-3835(18)30502.
    PubMed     Text format    


  4. KREITZBURG KM, Fehling SC, Landen CN, Gamblin TL, et al
    FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
    Cancer Lett. 2018 Aug 15. pii: S0304-3835(18)30527.
    PubMed     Text format     Abstract available


  5. CHEN X, Zhou J, Li X, Wang X, et al
    Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype.
    Cancer Lett. 2018;435:80-91.
    PubMed     Text format     Abstract available


    July 2018
  6. KARTHIKEYAN S, Russo A, Dean M, Lantvit DD, et al
    Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model.
    Cancer Lett. 2018;433:221-231.
    PubMed     Text format     Abstract available


    June 2018
  7. MALDONADO L, Brait M, Izumchenko E, Begum S, et al
    Integrated Transcriptomic and Epigenomic Analysis of Ovarian Cancer Reveals Epigenetically Silenced GULP1.
    Cancer Lett. 2018 Jun 28. pii: S0304-3835(18)30436.
    PubMed     Text format     Abstract available


    April 2018
  8. MENG Y, Chen CW, Yung MMH, Sun W, et al
    DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30296.
    PubMed     Text format     Abstract available


  9. LUO Q, Wu X, Zhang Y, Shu T, et al
    ARID1A ablation leads to Multiple Drug Resistance in ovarian cancer via transcriptional activation of MRP2.
    Cancer Lett. 2018 Apr 13. pii: S0304-3835(18)30274.
    PubMed     Text format     Abstract available


    March 2018
  10. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Text format     Abstract available


  11. VIRANI NA, Thavathiru E, McKernan P, Moore K, et al
    Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
    Cancer Lett. 2018 Mar 21. pii: S0304-3835(18)30224.
    PubMed     Text format     Abstract available


    February 2018
  12. HASSAN W, Chitcholtan K, Sykes P, Garrill A, et al
    Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.
    Cancer Lett. 2018 Feb 9. pii: S0304-3835(18)30140.
    PubMed     Text format     Abstract available


  13. RICCIARDELLI C, Lokman NA, Sabit I, Gunasegaran K, et al
    Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30131.
    PubMed     Text format     Abstract available


    December 2017
  14. YANG Z, Jin P, Xu S, Zhang T, et al
    Dicer reprograms stromal fibroblasts to a pro-inflammatory and tumor-promoting phenotype in ovarian cancer.
    Cancer Lett. 2017;415:20-29.
    PubMed     Text format     Abstract available


    November 2017
  15. TOMAR S, Plotnik JP, Haley J, Scantland J, et al
    ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
    Cancer Lett. 2017;414:190-204.
    PubMed     Text format     Abstract available


    October 2017
  16. YANG X, Wang CC, Lee WYW, Trovik J, et al
    Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30665.
    PubMed     Text format     Abstract available


  17. PISTOLLATO F, Calderon Iglesias R, Ruiz R, Aparicio S, et al
    The use of natural compounds for the targeting and chemoprevention of ovarian cancer.
    Cancer Lett. 2017 Oct 7. pii: S0304-3835(17)30619.
    PubMed     Text format     Abstract available


  18. SHU T, Li Y, Wu X, Li B, et al
    Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
    Cancer Lett. 2017 Oct 6. pii: S0304-3835(17)30609.
    PubMed     Text format     Abstract available


    September 2017
  19. LOUGHRAN EA, Phan RC, Leonard AK, Tarwater L, et al
    Multiparity Activates Interferon Pathways in Peritoneal Adipose Tissue and Decreases Susceptibility to Ovarian Cancer Metastasis in a Murine Allograft Model.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30581.
    PubMed     Text format     Abstract available


    July 2017
  20. SAKAI K, Ukita M, Schmidt J, Wu L, et al
    Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
    Cancer Lett. 2017 Jul 19. pii: S0304-3835(17)30439.
    PubMed     Text format     Abstract available


    May 2017
  21. LAKSHMINARASIMHAN R, Andreu-Vieyra C, Lawrenson K, Duymich CE, et al
    Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
    Cancer Lett. 2017 May 5. pii: S0304-3835(17)30312.
    PubMed     Text format     Abstract available


    April 2017
  22. SOKOLENKO AP, Savonevich EL, Ivantsov AO, Raskin GA, et al
    Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    Cancer Lett. 2017 Apr 1. pii: S0304-3835(17)30218.
    PubMed     Text format     Abstract available


    February 2017
  23. HU Y, Li D, Wu A, Qiu X, et al
    TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA.
    Cancer Lett. 2017 Feb 16. pii: S0304-3835(17)30109.
    PubMed     Text format     Abstract available


    January 2017
  24. DEAN M, Davis DA, Burdette JE
    Activin A Stimulates Migration of the Fallopian Tube Epithelium, an Origin of High-Grade Serous Ovarian Cancer, through Non-Canonical Signaling.
    Cancer Lett. 2017 Jan 20. pii: S0304-3835(17)30034.
    PubMed     Text format     Abstract available


    December 2016
  25. LUO T, Sun J, Zhu S, He J, et al
    Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
    Cancer Lett. 2016 Dec 30. pii: S0304-3835(16)30802.
    PubMed     Text format     Abstract available


  26. TODESCHINI P, Salviato E, Paracchini L, Ferracin M, et al
    Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: a validation across two independent cohorts.
    Cancer Lett. 2016 Dec 22. pii: S0304-3835(16)30780.
    PubMed     Text format     Abstract available


  27. AUER K, Bachmayr-Heyda A, Aust S, Grunt TW, et al
    Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer.
    Cancer Lett. 2016 Dec 7. pii: S0304-3835(16)30739.
    PubMed     Text format     Abstract available


    November 2016
  28. JEONG JY, Kang HY, Kim TH, Kim GI, et al
    MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Cancer Lett. 2016 Nov 22. pii: S0304-3835(16)30705.
    PubMed     Text format     Abstract available


    September 2016
  29. YOU J, Liu J, Bao Y, Wang L, et al
    SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.
    Cancer Lett. 2016 Sep 30. pii: S0304-3835(16)30574.
    PubMed     Text format     Abstract available


  30. LI Q, Zhang C, Chen R, Xiong H, et al
    Disrupting MALAT1/miR-200c sponge decreases invasion and migration in endometrioid endometrial carcinoma.
    Cancer Lett. 2016 Sep 28. pii: S0304-3835(16)30561.
    PubMed     Text format     Abstract available


    March 2016
  31. TONG H, Ke JQ, Jiang FZ, Wang XJ, et al
    Tumor-associated macrophage-derived CXCL8 could induce ERalpha suppression via HOXB13 in endometrial cancer.
    Cancer Lett. 2016 Mar 24. pii: S0304-3835(16)30196.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: